Literature DB >> 31807990

Screening for impaired liver function as a risk factor for drug safety at hospital admission of surgical patients.

Dorothea Strobach1,2, Angelika Poppele3,4, Hanna Mannell5, Monika Andraschko3, Susanne Schiek4, Thilo Bertsche4.   

Abstract

Background Hepatic insufficiency can affect patient safety and should therefore be considered during drug therapy. Hospital admission offers an ideal point to screen for patients at risk and to adjust drug therapy accordingly. Objective To assess the number of patients admitted to hospital with clinically elevated liver parameters. To identify high-risk patients in need of potential drug therapy adjustment to liver function by calculation of liver scores. Finally, to investigate whether pre-hospital medication needed adjustment to liver function. Setting Patients admitted to surgical wards of a tertiary teaching hospital. Method Surgical patients were included in a 3-month retrospective study. A pharmacist-led screening process, including recording of elevated liver parameters and calculation of liver scores (Child-Pugh-score, Model of End-stage Liver Disase [MELD], MELDNa), was used to assess frequency of hepatic insufficiency and patients potentially needing medication adjustment. Additionally, pre-hospital medication was checked for contraindications and correct dosage with regard to liver function. Main outcome measure Percentage of surgical patients with clinically elevated liver parameters at admission, percentage of patients with hepatic insufficiency potentially needing drug therapy adjustment, and percentage of pre-hospital drug intakes not adjusted to liver function. Results Of 1200 patients, 130 (11%) had at least one clinically relevant elevated liver parameter at hospital admission. Of these, need for drug adjustment to liver function was found for 16-36%, depending on the liver score used (equivalent to 2-4% of all patients), with the highest number of patients detected by the MELD- and MELDNa-score. Pre-hospital medication concerned 719 drug intakes and was contraindicated in 2%, dosage not adjusted in 3%, and evaluation not possible in 44% of all drug intakes due to lack of information on the drug. Conclusion A significant proportion of patients admitted for surgery have clinically elevated liver parameters and potentially need medication adjustment. A pharmacist-led screening already at hospital admission can support the identification of patients with clinically relevant elevated liver parameters and patients at risk by calculating liver scores under routine conditions. Evaluation of drug adjustment to liver function is challenging, since no data are available in routine resources for a considerable number of drugs.

Entities:  

Keywords:  Drug safety; Hepatic insufficiency; Hospital stay; Patient safety; Pharmacists

Year:  2019        PMID: 31807990     DOI: 10.1007/s11096-019-00948-7

Source DB:  PubMed          Journal:  Int J Clin Pharm


  32 in total

1.  Low prevalence of chronic hepatitis C, but high prevalence of elevated aminotransferases in a cohort of 2026 patients referred for orthopaedic surgery in the eastern part of Germany.

Authors:  J Wiegand; T Kaiser; S Lobstein; F Brand; M Wojan; U Stölzel; U G Liebert; J Mössner; H L Tillmann
Journal:  Z Gastroenterol       Date:  2006-01       Impact factor: 2.000

Review 2.  Age-related pharmacokinetic and pharmacodynamic changes and related risk of adverse drug reactions.

Authors:  A Corsonello; C Pedone; R A Incalzi
Journal:  Curr Med Chem       Date:  2010       Impact factor: 4.530

3.  Discrepancies in liver disease labeling in the package inserts of commonly prescribed medications.

Authors:  Einar S Bjornsson; Elin I Jacobsen; Rannveig Einarsdottir; Naga Chalasani
Journal:  Gastroenterology       Date:  2014-12-18       Impact factor: 22.682

4.  Comparison of the prognostic value of Chronic Liver Failure Consortium scores and traditional models for predicting mortality in patients with cirrhosis.

Authors:  Artur Gião Antunes; Cristina Teixeira; Ana Margarida Vaz; Cláudio Martins; Patrícia Queirós; Ana Alves; Francisco Velasco; Bruno Peixe; Ana Paula Oliveira; Horácio Guerreiro
Journal:  Gastroenterol Hepatol       Date:  2017-02-20       Impact factor: 2.102

5.  Comparison of four models for end-stage liver disease in evaluating the prognosis of cirrhosis.

Authors:  Ming Jiang; Fei Liu; Wu-Jun Xiong; Lan Zhong; Xi-Mei Chen
Journal:  World J Gastroenterol       Date:  2008-11-14       Impact factor: 5.742

6.  Elevated liver enzyme activity in construction workers: prevalence and impact on early retirement and all-cause mortality.

Authors:  V Arndt; H Brenner; D Rothenbacher; B Zschenderlein; E Fraisse; T M Fliedner
Journal:  Int Arch Occup Environ Health       Date:  1998-09       Impact factor: 3.015

Review 7.  [ALT screening for chronic liver diseases: scrutinizing the evidence].

Authors:  H Wedemeyer; W P Hofmann; S Lueth; P Malinski; R Thimme; F Tacke; J Wiegand
Journal:  Z Gastroenterol       Date:  2010-01-13       Impact factor: 2.000

Review 8.  Hospitalization in older patients due to adverse drug reactions -the need for a prediction tool.

Authors:  Nibu Parameswaran Nair; Leanne Chalmers; Gregory M Peterson; Bonnie J Bereznicki; Ronald L Castelino; Luke R Bereznicki
Journal:  Clin Interv Aging       Date:  2016-05-02       Impact factor: 4.458

9.  MELD score as a predictor of mortality, length of hospital stay, and disease burden: A single-center retrospective study in 39,323 inpatients.

Authors:  Jan A Roth; Carl Chrobak; Sabine Schädelin; Balthasar L Hug
Journal:  Medicine (Baltimore)       Date:  2017-06       Impact factor: 1.817

Review 10.  Evidence-Based Recommendations to Improve the Safe Use of Drugs in Patients with Liver Cirrhosis.

Authors:  Rianne A Weersink; Margriet Bouma; David M Burger; Joost P H Drenth; S Froukje Harkes-Idzinga; Nicole G M Hunfeld; Herold J Metselaar; Margje H Monster-Simons; Katja Taxis; Sander D Borgsteede
Journal:  Drug Saf       Date:  2018-06       Impact factor: 5.606

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.